IL-1B rs1143623 and EEF1A1P11-RPL7P9 rs10783050 polymorphisms affect the glucose-lowing efficacy of metformin in Chinese overweight or obese Type 2 diabetes mellitus patients

Pharmacogenomics. 2015;16(14):1621-9. doi: 10.2217/pgs.15.95. Epub 2015 Sep 24.

Abstract

Aim: To investigate the potential genetic effect on metformin efficacy in overweight or obese Chinese Type 2 diabetes mellitus (T2DM) patients.

Patients & methods: 768 SNPs in or close to 207 genes were genotyped in 84 patients treated with metformin + glibenclamide/Xiaoke Pill. Significant SNPs were then verified in 107 recent-onset overweight or obese T2DM patients treated with metformin alone. Genotyping was done by Illumina GoldenGate Assay.

Results: In the discovery stage, 22 SNPs were nominally significant. IL1B rs1143623 (p = 0.011) and EEF1A1P11-RPL7P9 rs10783050 (p = 0.021) were still significantly associated with the relative change of HbA1c in the replication stage.

Conclusion: IL1B rs1143623 and EEF1A1P11-RPL7P9 rs10783050 polymorphisms may contribute to metformin's glucose-lowing efficacy in overweight or obese Chinese T2DM patients.

Keywords: SNP; Type 2 diabetes mellitus; glucose-lowing efficacy; metformin; obese; overweight; pharmacogenomics.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Asian People
  • Diabetes Mellitus, Type 2 / complications
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Diabetes Mellitus, Type 2 / genetics*
  • Female
  • Genotype
  • Glycated Hemoglobin / analysis
  • Humans
  • Hypoglycemic Agents / therapeutic use*
  • Interleukin-1beta / genetics*
  • Male
  • Metformin / therapeutic use*
  • Middle Aged
  • Obesity / complications*
  • Overweight / complications*
  • Polymorphism, Genetic / genetics*
  • Polymorphism, Single Nucleotide

Substances

  • Glycated Hemoglobin A
  • Hypoglycemic Agents
  • IL1B protein, human
  • Interleukin-1beta
  • Metformin